showed a trendP = 0.089
Post-therapeutic SHOX2 and SEPT9 ccfDNA methylation in matched samples from individual patients, however, showed a trend towards decreased levels in 70 patients with localised (M 0 , SEPT9 : P = 0.089, SHOX2 : P = 0.13) disease and no decrease in 9 patients with distant metastases (M 1 , SEPT9 : P = 0.67, SHOX2 : P = 0.52) (Fig. 4 ).